Research·October 25, 2026 at 11:30 AM EDT·1 source
#ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial
AMGN -1.8%BMY
AMGN · last 30 trading days-1.8% since the news
News
What happened
- Roche’s next-generation KRAS G12C inhibitor reduced the risk of death by 44% in previously treated mutant non-small cell lung cancer.
- The drug was tested head-to-head against KRAS G12C inhibitors from Amgen and Bristol Myers Squibb.
Reduction in risk of death
44%
Why it matters
The results could affect competitive positioning in the KRAS G12C inhibitor market and inform healthcare investors tracking lung-cancer treatments.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 23Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
- EarlierYesterdayAmgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
- Earlier10h#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
- Earlier4hRoche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study
- First reported by Endpoints News4h#ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial
Who is involved
#ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s…RocheAmgenAMGNBristol Myers SquibbBMY
Company
Sources (1)
Related
- 4h · Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study
- 10h · #ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
- Yesterday · Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
- Oct 23 · Bristol Myers reveals autoimmune CAR-T trial death, explains summertime pause
- Oct 23 · Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
- Oct 18 · Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.